BSF Enterprise shares jump on paper in praise of "T-rex leather"

(Alliance News) - BSF Enterprise on Tuesday saw its shares rise after the publication of a paper on one of its subsidiaries' synthetic leather products.

The London-based biotech company's shares jumped 49% to 3.35 pence on Tuesday in London.

BSF Enterprise owns Lab-Grown Leather Ltd, the Newcastle-upon-Tyne, England-based materials specialist, focused on products for luxury and high-performance markets.

LGL is also the developer of "T-rex leather", in partnership with the Organoid Co. The product is based on reconstructions of "the collagen blueprint

of a Tyrannosaurus rex using AI-assisted computational modelling", BSF Enterprise said.

It sees T-rex leather overcoming "the perception of imitation" that hangs over the synthetic leather market, going so far as to suggest that the technology "subverts the deeply entrenched socio-economic paradigms ruling the global luxury fashion industry".

"This paradigm shift aligns closely with ongoing changes in multinational corporate sustainability and ESG compliance," BSF Enterprise continued.

It expects to capitalise on growth in the leather, smart textile and integrated textile markets. LGL will auction a T-rex leather handbag in Paris next week.

More broadly, BSF Enterprise said the project can serve as a proof of concept for reconstructing extinct proteins, applicable across the biopharmaceutical, chemical, and cosmetic sectors.

According to BSF Enterprise, pharmaceutical majors such as Eli Lilly & Co, Novartis AG, Johnson & Johnson, Bristol Myers Squibb Co, Novo Nordisk AS, AstraZeneca PLC and Takeda Pharmaceutical Co Ltd, "are using similar AI-driven protein folding models and these digital biology tools are drastically accelerating the drug discovery cycle."

BASF SE, Evonik Industries AG and L'Oreal SA are replacing animal-based ingredients with "bio-designed collagens", BSF Enterprise added.

Last month, BSF Enterprise had said it was considering subsidiary-level financing options for LGL, including a potential spin-out.

By Holly Munks, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Bio-Sustainable Future Enterprises

Astrazeneca